What's Happening?
Eli Lilly's experimental weight loss drug, Retatrutide, has shown promising results in clinical trials, with participants losing up to 28% of their body weight over 80 weeks. The drug, known as 'Triple G,' mimics three hormones involved in appetite and
metabolism, offering greater weight loss than existing drugs like Ozempic and Mounjaro. While not yet FDA-approved, Retatrutide is available to some patients through the FDA's compassionate use program. Eli Lilly plans to submit the drug for FDA approval in early 2027, with a potential market release following a year-long review process.
Why It's Important?
Retatrutide represents a significant advancement in weight loss treatment, particularly for individuals with type 2 diabetes who struggle with obesity. The drug's ability to mimic multiple hormones involved in metabolism could offer a more effective solution for weight management. If approved, Retatrutide could provide a new option for patients who have not responded to existing treatments, potentially improving health outcomes and quality of life for many individuals.
What's Next?
Eli Lilly is preparing to submit Retatrutide for FDA approval, with the review process expected to take up to a year. In the meantime, the company is expanding access to the drug through compassionate use programs. The outcome of the FDA's review will determine the drug's availability on the market, and its classification as a biologic or peptide will impact its market exclusivity and competition from generic alternatives.
